172 related articles for article (PubMed ID: 34305895)
1. Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient.
Lai C; Liu X; Yan Q; Lv H; Zhou L; Hu L; Cai Y; Wang G; Chen Y; Chai R; Liu Z; Xu Y; Huang W; Xiao F; Hu L; Li Y; Huang J; Zhou Q; Li L; Peng T; Zhang H; Zhang Z; Chen L; Chen C; Ji T
Front Immunol; 2021; 12():664619. PubMed ID: 34305895
[TBL] [Abstract][Full Text] [Related]
2. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
Jalkanen P; Pasternack A; Maljanen S; Melén K; Kolehmainen P; Huttunen M; Lundberg R; Tripathi L; Khan H; Ritvos MA; Naves R; Haveri A; Österlund P; Kuivanen S; Jääskeläinen AJ; Kurkela S; Lappalainen M; Rantasärkkä K; Vuorinen T; Hytönen J; Waris M; Tauriainen S; Ritvos O; Kakkola L; Julkunen I
J Infect Dis; 2021 Jul; 224(2):218-228. PubMed ID: 33905505
[TBL] [Abstract][Full Text] [Related]
3. Pre-pandemic antibodies screening against SARS-CoV-2 and virus detection among children diagnosed with eruptive fevers.
Najimi N; Tajount L; Regragui Z; Remz C; Ait-Lhaj-Mhand R; Kadi C; Belayachi L; Seghrouchni F; Nadia Dakka ; El Hassani RA; Elharti E; Oumzil H; Bakri Y
Int J Immunopathol Pharmacol; 2024; 38():3946320241260633. PubMed ID: 38836458
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC
mBio; 2021 Jan; 12(1):. PubMed ID: 33468695
[TBL] [Abstract][Full Text] [Related]
5. Profile of specific antibodies to the SARS-CoV-2.
Mou D; Feng H; Cao R; Weng X; Zhao L; Yang L; Jin R; Chen W
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33734961
[TBL] [Abstract][Full Text] [Related]
6. Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection.
Manisty C; Treibel TA; Jensen M; Semper A; Joy G; Gupta RK; Cutino-Moguel T; Andiapen M; Jones J; Taylor S; Otter A; Pade C; Gibbons J; Lee J; Bacon J; Thomas S; Moon C; Jones M; Williams D; Lambourne J; Fontana M; Altmann DM; Boyton R; Maini M; McKnight A; Chain B; Noursadeghi M; Moon JC
EBioMedicine; 2021 Mar; 65():103259. PubMed ID: 33662833
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Crawford KHD; Dingens AS; Eguia R; Wolf CR; Wilcox N; Logue JK; Shuey K; Casto AM; Fiala B; Wrenn S; Pettie D; King NP; Greninger AL; Chu HY; Bloom JD
J Infect Dis; 2021 Feb; 223(2):197-205. PubMed ID: 33535236
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.
Secchi M; Bazzigaluppi E; Brigatti C; Marzinotto I; Tresoldi C; Rovere-Querini P; Poli A; Castagna A; Scarlatti G; Zangrillo A; Ciceri F; Piemonti L; Lampasona V
J Clin Invest; 2020 Dec; 130(12):6366-6378. PubMed ID: 32991329
[TBL] [Abstract][Full Text] [Related]
9. Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection.
Movsisyan M; Truzyan N; Kasparova I; Chopikyan A; Sawaqed R; Bedross A; Sukiasyan M; Dilbaryan K; Shariff S; Kwantala B; Hakobjanyan G; Petrosyan G; Hakobyan A; Yenkoyan K
Sci Rep; 2024 Jun; 14(1):13417. PubMed ID: 38862731
[TBL] [Abstract][Full Text] [Related]
10. The kinetics of humoral response and its relationship with the disease severity in COVID-19.
Ren L; Zhang L; Chang D; Wang J; Hu Y; Chen H; Guo L; Wu C; Wang C; Wang Y; Wang Y; Wang G; Yang S; Dela Cruz CS; Sharma L; Wang L; Zhang D; Wang J
Commun Biol; 2020 Dec; 3(1):780. PubMed ID: 33311543
[TBL] [Abstract][Full Text] [Related]
11. Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection.
Ratcliff J; Nguyen D; Fish M; Rynne J; Jennings A; Williams S; Al-Beidh F; Bonsall D; Evans A; Golubchik T; Gordon AC; Lamikanra A; Tsang P; Ciccone NA; Leuscher U; Slack W; Laing E; Mouncey PR; Ziyenge S; Oliveira M; Ploeg R; Rowan KM; Shankar-Hari M; Roberts DJ; Menon DK; Estcourt L; Simmonds P; Harvala H;
J Infect Dis; 2021 Aug; 224(4):595-605. PubMed ID: 34031695
[TBL] [Abstract][Full Text] [Related]
12. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.
Murrell I; Forde D; Zelek W; Tyson L; Chichester L; Palmer N; Jones R; Morgan BP; Moore C
PLoS One; 2021; 16(1):e0245382. PubMed ID: 33497420
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.
Figueiredo-Campos P; Blankenhaus B; Mota C; Gomes A; Serrano M; Ariotti S; Costa C; Nunes-Cabaço H; Mendes AM; Gaspar P; Pereira-Santos MC; Rodrigues F; Condeço J; Escoval MA; Santos M; Ramirez M; Melo-Cristino J; Simas JP; Vasconcelos E; Afonso Â; Veldhoen M
Eur J Immunol; 2020 Dec; 50(12):2025-2040. PubMed ID: 33084029
[TBL] [Abstract][Full Text] [Related]
14. Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection.
Horspool AM; Kieffer T; Russ BP; DeJong MA; Wolf MA; Karakiozis JM; Hickey BJ; Fagone P; Tacker DH; Bevere JR; Martinez I; Barbier M; Perrotta PL; Damron FH
mSphere; 2021 Jan; 6(1):. PubMed ID: 33472985
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
Li D; Edwards RJ; Manne K; Martinez DR; Schäfer A; Alam SM; Wiehe K; Lu X; Parks R; Sutherland LL; Oguin TH; McDanal C; Perez LG; Mansouri K; Gobeil SMC; Janowska K; Stalls V; Kopp M; Cai F; Lee E; Foulger A; Hernandez GE; Sanzone A; Tilahun K; Jiang C; Tse LV; Bock KW; Minai M; Nagata BM; Cronin K; Gee-Lai V; Deyton M; Barr M; Von Holle T; Macintyre AN; Stover E; Feldman J; Hauser BM; Caradonna TM; Scobey TD; Rountree W; Wang Y; Moody MA; Cain DW; DeMarco CT; Denny TN; Woods CW; Petzold EW; Schmidt AG; Teng IT; Zhou T; Kwong PD; Mascola JR; Graham BS; Moore IN; Seder R; Andersen H; Lewis MG; Montefiori DC; Sempowski GD; Baric RS; Acharya P; Haynes BF; Saunders KO
Cell; 2021 Aug; 184(16):4203-4219.e32. PubMed ID: 34242577
[TBL] [Abstract][Full Text] [Related]
16. Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks.
Gallichotte EN; Nehring M; Young MC; Pugh S; Sexton NR; Fitzmeyer E; Quicke KM; Richardson M; Pabilonia KL; Ehrhart N; Fosdick BK; VandeWoude S; Ebel GD
Microbiol Spectr; 2021 Sep; 9(1):e0022421. PubMed ID: 34287058
[TBL] [Abstract][Full Text] [Related]
17. Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients.
Thieme CJ; Anft M; Paniskaki K; Blazquez-Navarro A; Doevelaar A; Seibert FS; Hoelzer B; Konik MJ; Berger MM; Brenner T; Tempfer C; Watzl C; Meister TL; Pfaender S; Steinmann E; Dolff S; Dittmer U; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
Cell Rep Med; 2020 Sep; 1(6):100092. PubMed ID: 32904468
[TBL] [Abstract][Full Text] [Related]
18. Age dependent discrepancy between SARS-CoV-2 anti-nucleoprotein antibody and anti-RBD spike protein antibody in children reflects vaccine coverage.
Fujii Y; Ishigaki H; Miyairi I; Niizeki N; Nagura O; Yamashita K; Maekawa M; Furuhashi K
J Infect Chemother; 2024 Jul; 30(7):646-650. PubMed ID: 38309499
[TBL] [Abstract][Full Text] [Related]
19. Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19.
Kawasuji H; Morinaga Y; Tani H; Kimura M; Yamada H; Yoshida Y; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Kawago K; Fukui Y; Sakamaki I; Yamamoto Y
Sci Rep; 2021 Aug; 11(1):16535. PubMed ID: 34400739
[TBL] [Abstract][Full Text] [Related]
20. Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19.
Han Y; Liu P; Qiu Y; Zhou J; Liu Y; Hu X; Yang Q; Huang R; Wen X; Song H; Yu P; Yang M; Zhang J; Liu WJ; Peng K; Wu G; Zhang D; Zhou X; Wu Y
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33476301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
